Gilead�s $21 billion purchase of Immunomedics boosts ADC field
Update: 2025-10-09
Description
In the largest deal in its 33-year history, Gilead Sciences has agreed to pay $21 billion to acquire Immunomedics and its recently-approved antibody-drug conjugate or ADC, Trodelvy.Immunomedics has a full pipeline of antibodies and ADCs, but the clear target of the deal was Trodelvy, which the US Fo....
This item belongs to: audio/rivet360-audio-collection.
This item has files of the following types: Archive BitTorrent, Metadata, VBR MP3
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
